Testicular cancer has a peak incidence at around 30 years of age, and it is the most common cancer in men under 35 years of age, accounting for a third of all cancers in that age range (Adami et al, 1994). The age distribution is unusual among adult malignancies, with almost 70 % of cases arising in men under 40 years of age, and only about 2 % in men over 70 years of age. Incidence has increased steadily in many developed countries over the last 50 years, including the United Kingdom (Coleman et al, 1993; Richiardi et al, 2004). In men under 50 years of age, incidence has risen almost two-fold in England and Wales in the last 30 years, but the increase has been much smaller among older men (Quinn et al, 2001). Age-standardised mortality wa...
The incidence of testicular cancer has been increasing markedly in most industrialised countries. Th...
SummaryBackgroundAssessment of progress in cancer control at the population level is increasingly im...
International audienceEffective treatments for testicular cancer have been available since the 1970s...
Item does not contain fulltextAbstract Background. Worldwide marked changes have been observed in th...
This study profiles testicular cancer incidence and mortality across Europe, and the effects of age,...
Within the last 10 years, prostate cancer has become the most common malignancy among men in England...
OBJECTIVES: To compare the relative survival in men younger and older than 50 years with a testicula...
Testicular cancer is a relatively rare dis-ease, accounting for only 1.1 % of all malig-nant neoplas...
Statistics, 2003). Bladder cancer ranks as the fourth most common in men and ninth in women, and it ...
The aim of our study was to interpret the changing incidence, and to describe the mortality of patie...
Effective treatments for testicular cancer have been available since the 1970s, yet EURO-CARE uncove...
Background: Testicular cancer is the most common cancer in men under 35 years of age, and has the hi...
Effective treatments for testicular cancer have been available since the 1970s, yet EURO-CARE uncove...
The aim of our study was to interpret the changing incidence, and to describe the mortality of patie...
BACKGROUND: Assessment of progress in cancer control at the population level is increasingly importa...
The incidence of testicular cancer has been increasing markedly in most industrialised countries. Th...
SummaryBackgroundAssessment of progress in cancer control at the population level is increasingly im...
International audienceEffective treatments for testicular cancer have been available since the 1970s...
Item does not contain fulltextAbstract Background. Worldwide marked changes have been observed in th...
This study profiles testicular cancer incidence and mortality across Europe, and the effects of age,...
Within the last 10 years, prostate cancer has become the most common malignancy among men in England...
OBJECTIVES: To compare the relative survival in men younger and older than 50 years with a testicula...
Testicular cancer is a relatively rare dis-ease, accounting for only 1.1 % of all malig-nant neoplas...
Statistics, 2003). Bladder cancer ranks as the fourth most common in men and ninth in women, and it ...
The aim of our study was to interpret the changing incidence, and to describe the mortality of patie...
Effective treatments for testicular cancer have been available since the 1970s, yet EURO-CARE uncove...
Background: Testicular cancer is the most common cancer in men under 35 years of age, and has the hi...
Effective treatments for testicular cancer have been available since the 1970s, yet EURO-CARE uncove...
The aim of our study was to interpret the changing incidence, and to describe the mortality of patie...
BACKGROUND: Assessment of progress in cancer control at the population level is increasingly importa...
The incidence of testicular cancer has been increasing markedly in most industrialised countries. Th...
SummaryBackgroundAssessment of progress in cancer control at the population level is increasingly im...
International audienceEffective treatments for testicular cancer have been available since the 1970s...